A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
RECOMMENDATIONS 1. Pharmacotherapy for obesity management can be used for individuals with a BMI ≥30 kg/m2, or ≥27 kg/m2 with adiposity-related complications, in conjunction with medical nutrition therapy, physical activity and psychological interven…
BACKGROUND: Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD) and kidney failure globally. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduces the risk of major kidney, cardiovascular and mortality outcom…
Obesity, type 2 diabetes mellitus and associated thyroid diseases are most common among elderly patients. Glucagon-like peptide-1 receptor (GLP-1-R) agonists, including semaglutide, are a promising approach for their treatment, but their effects on m…
AIMS: GLP-1 receptor agonists, such as semaglutide (Ozempic) and tirzepatide (Monjaro), have gained significant popularity for obesity management, but concerns have arisen about their potential link to thyroid cancer. This study investigates the asso…
In this narrative review we describe the recent updates regarding anti-obesity medications as of February 2025. We describe the physiologic mechanisms underpinning the development of hunger, satiation, and maintenance of satiety to address targets fo…
INTRODUCTION AND OBJECTIVES: Disruptions in one-carbon metabolism (OCM) have been linked to cardiometabolic diseases. We evaluated alterations in OCM metabolites and enzymes and the impact of semaglutide in MASLD. MATERIALS AND METHODS: Using targete…
OBJECTIVE: The objective of this study was to examine weight reduction and adverse events associated with use of antiobesity medications (AOMs) in older adults ages ≥65 years. METHODS: Seven databases were searched for studies evaluating weight reduc…
OBJECTIVE: Using national claims databases, we sought to emulate the design of the ongoing SEPRA trial and predict its findings, comparing the effects of once weekly semaglutide to SoC medications on glycemic control (A1C <7%) in type-2 diabetes mell…
Sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated renal benefits beyond glycemic control in patients with type 2 diabetes mellitus (T2DM). This study compares renal outcomes and…
BACKGROUND AND AIMS: The Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial demonstrated significant reductions in cardiovascular outcomes in people with cardiovascular disease (CVD) and overweight or o…
This systematic review examines the potential association between semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and the development of non-arteritic anterior ischemic optic neuropathy (NAION). Nine studies were included, consisting…
BACKGROUND: The American Diabetes Association recommends the use of glucagon-like-peptide-1 receptor agonists (GLP1-RAs) (e.g., Ozempic) for patients with atherosclerotic cardiovascular disease, including peripheral artery disease. We hypothesized in…
BACKGROUND: Clinical experience with semaglutide in patients with type 2 diabetes mellitus shows that its benefits extend far beyond glucose regulation. This study examines whether this drug is indeed popular among the Croatian population and explore…
BACKGROUND: In recent years, there has been a dramatic increase in the popularity and use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss. As such, it is essential to understand users' real-world discussions of short-term, lo…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) potentially increase the risk of pulmonary aspiration resulting from impaired gastric emptying (IGE). We evaluated the association between GLP-1RAs and IGE using the US Food and Drug Ad…
Obesity management is complex; medications must be used in conjunction with behavioural changes and monitoring by health professionals. Injectable drugs for weight management include glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. liraglutide…
Rhabdomyolysis is a clinical syndrome characterized by the breakdown of skeletal muscle, leading to the release of creatine kinase (CK), myoglobin and electrolytes into the circulation. This can result in acute kidney injury and other complications.…